IDEXX Laboratories, Inc. (IDXX)
Automate Your Wheel Strategy on IDXX
With Tiblio's Option Bot, you can configure your own wheel strategy including IDXX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IDXX
- Rev/Share 50.2122
- Book/Share 18.1417
- PB 35.0965
- Debt/Equity 0.8481
- CurrentRatio 1.1131
- ROIC 0.3616
- MktCap 50939792537.0
- FreeCF/Share 9.6295
- PFCF 65.785
- PE 51.9449
- Debt/Assets 0.3715
- DivYield 0
- ROE 0.6442
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | IDXX | BTIG Research | -- | Buy | $545 | $785 | Aug. 5, 2025 |
| Initiation | IDXX | Jefferies | -- | Buy | -- | $625 | July 1, 2025 |
News
Is Idexx (IDXX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Idexx Laboratories (IDXX) is a Top Momentum Stock for the Long-Term
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
IDEXX Laboratories, Inc. (IDXX) Q2 2025 Earnings Call Transcript
Published: August 04, 2025 by: Seeking Alpha
Sentiment: Neutral
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jonathan J. Mazelsky - President, CEO & Director Conference Call Participants Christopher Thomas Schott - JPMorgan Chase & Co, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Erin Elizabeth Wilson Wright - Morgan Stanley, Research Division Jonathan David Block - Stifel, Nicolaus & Company, Incorporated, Research Division Michael Leonidovich Ryskin - BofA Securities, Research Division Navann Ty Dietschi - BNP Paribas …
Read More
Final Trades: Delta Air Lines, Tesla, Idexx Lab and the IYF
Published: August 04, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee gives you their top stocks to watch for the second half.
Read More
Top Stock Movers Now: IDEXX, Wayfair, Berkshire Hathaway, and More
Published: August 04, 2025 by: Investopedia
Sentiment: Positive
U.S. equities were higher at midday, bouncing back from Friday's employment report-related selloff, and on news the European Union would delay new tariffs on U.S. goods. The Dow Jones Industrial Average, S&P 500, and Nasdaq all rose.
Read More
IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
IDXX posts double-digit Q2 revenue growth, beats EPS estimates and lifts the full-year outlook as margins rise sharply.
Read More
Idexx (IDXX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
IDEXX Laboratories Stock Jumps as Pet Health Care Firm Lifts Full-Year Outlook
Published: August 04, 2025 by: Investopedia
Sentiment: Positive
Shares of IDEXX Laboratories (IDXX) soared more than 10% in premarket trading Monday after the pet health care company reported better-than-expected second-quarter results and raised its 2025 profit and revenue forecasts.
Read More
Idexx (IDXX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Idexx (IDXX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Read More
IDEXX Releases 2024 Corporate Responsibility Report, Highlighting Progress Against Its Goals
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral
WESTBROOK, Maine , July 30, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today released its 2024 Corporate Responsibility Report "Enhancing the health and well-being of pets, people, and livestock" highlighting progress toward goals closely aligned with its Purpose and business strategy. The Care We Advance IDEXX brings clarity to the complex world of veterinary medicine through innovative diagnostic and software solutions.
Read More
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
IDEXX to Release Q2 Earnings: What's in Store for the Stock?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
IDXX eyes a Q2 earnings jump with CAG growth, global pricing gains, and momentum in water and software segments.
Read More
IDEXX Laboratories: A Business With Strong Fundamentals
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Positive
I rate IDEXX Laboratories a buy, driven by a lasting surge in pet ownership and IDXX's leadership in veterinary diagnostics. New platforms like inVue Dx and Cancer Dx provide additional growth drivers, with strong early adoption and potential for margin expansion. IDXX's recurring revenue model, robust retention, and expanding high-margin consumables base support sustained revenue and earnings growth.
Read More
Idexx (IDXX) is an Incredible Growth Stock: 3 Reasons Why
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
Read More
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
IDEXX Laboratories to Release 2025 Second Quarter Financial Results
Published: June 24, 2025 by: Business Wire
Sentiment: Neutral
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2025 Earnings Snapshot through a link on the IDEXX websi.
Read More
Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders
Published: June 05, 2025 by: PRNewsWire
Sentiment: Neutral
The Catalyst ® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndrome WESTBROOK, Maine , June 5, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. IDEXX's Catalyst Cortisol Test is the third menu expansion in under a year for the Catalyst platform, further advancing the diagnostic capabilities available to veterinary practices at the point-of-care.
Read More
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
Read More
IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and margin expansion.
Read More
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Read More
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day
Published: May 13, 2025 by: Business Wire
Sentiment: Neutral
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation will be available through a link on.
Read More
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
IDEXX Laboratories, Inc. (IDXX) Q1 2025 Earnings Conference Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Emerson - EVP, CFO and Treasurer Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Brandon Vazquez - William Blair Dan Clark - Leerink Partners David Westenberg - Piper Sandler Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' First Quarter 2025 Earnings Conference Call. As a reminder, today's conference is being recorded.
Read More
Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.81 per share a year ago.
Read More
IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics
Published: May 01, 2025 by: Reuters
Sentiment: Positive
Animal diagnostics maker IDEXX Laboratories on Thursday raised its annual profit forecast after it beat Wall Street estimates for quarterly profit, as it benefited from customer retention and increased demand for its tests and equipment.
Read More
IDEXX Laboratories Announces First Quarter Results
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. “IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, IDEXX Cancer Dx™, in our North American reference laboratories,” said Jay Mazelsky, President and Chief Executive Officer. “Customers have been askin.
Read More
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Read More
IDXX Gears Up for Q1 Earnings: What to Expect From the Stock?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
IDEXX Laboratories' first-quarter 2025 performance is expected to have benefited from a strong execution against strategic priorities.
Read More
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
About IDEXX Laboratories, Inc. (IDXX)
- IPO Date 1991-06-21
- Website https://www.idexx.com
- Industry Medical - Diagnostics & Research
- CEO Jonathan J. Mazelsky
- Employees 11000